Fecal Transplant for Hepatic Encephalopathy

Phase 1

Completed

• Conditions: Hepatic Encephalopathy
• Interventions: Biological: FMT

• Registration Number: NCT03439982
• Lead Sponsor: University of Alberta

Brief Summary

The purpose of the study is to determine if fecal microbiota transplant (FMT) can reverse hepatic encephalopathy (HE) in cirrhotic patients who continue to have breakthrough episodes of HE despite maintenance therapy with lactulose and/or rifaximin or metronidazole.

Detailed Description

Subjects receive FMT from a single donor by colonoscopy at week 0 and by enema at weeks 1-4. HE is measured by Inhibitory Control Test (ICT) and Stroop test as well as fasting serum ammonia levels.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2016-04-12
• Study First Submitted: 2018-02-13
• Study First Submitted QC: 2018-02-13
• Study First Posted: 2018-02-20
• Primary Completion: 2019-08-07
• Study Completion: 2021-03-18
• Status Verified: 2021-07
• Last Update Submitted: 2022-06-07
• Last Update Posted: 2022-06-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

• Adult cirrhotic patients of various etiology on lactulose and/pr rifaximin or metronidazole for minimum 4 weeks as secondary prophylaxis
• Abnormal ICT (>5 lures) or abnormal Stroop test (>200 seconds)
• Baseline Conn score 0 or 1
• Infectious etiology of HE has been ruled out

Read More

Exclusion Criteria

• those with tense ascites
• those who do not provide assent
• life expectancy <3 months
• TIPS within the past 3 months
• neurologic disease such as dementia, Parkinson's, structural brain lesions
• pregnancy
• intestinal obstruction
• alcoholic hepatitis
• active alcohol or substance abuse
• those without stable social support
• concurrent infection such as spontaneous bacterial peritonitis, pneumonia or urinary tract infection
• creatinine clearance less that 50% compared to baseline
• hospital admission for HE within one month of enrollment
• active hepatocellular carcinoma
• active GI bleed

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
FMT	FMT	Open label FMT administered at week 0 by colonoscopy and weeks 1-4 by enema

Primary Outcome Measures

Name	Time	Method
Portion of participants with normalization of ICT or Stroop Test during the study	8 weeks

Secondary Outcome Measures

Name	Time	Method
Changes in serum ammonia level pre and post FMT	8 weeks
Proportion of patients with normalization ICT or Stroop test scores at 1 week, 2 weeks, 4 weeks and 8	8 weeks
Changes in Quality of Life measured by Chronic Liver Disease Questionnaire (CDLQ) pre and post FMT	8 weeks	29 Questions Total- each question is on a seven point scales, ranging from the worst (1) to the best (7) possible function
Change in Intestinal Microbiota pre-and post FMT	8 weeks
Serious Adverse Events	8 weeks	i) All serious adverse events up to and including week 8. A serious adverse event is any event which results in any of the following: i) Death ii) Colonic perforation iii) Proven infections as defined by the presence of i) spontaneous bacteremia: positive blood cultures in the absence of any other potential source of infection; ii) spontaneous bacterial peritonitis: ascetic fluid PMN equal to or greater than 250/mm3; iii) UTI: urinary leukocyte count greater than 15 cells per HPF and positive urine culture; vi) other infections identified by clinical, radiologic and bacteriologic results.; iv) Possible infections as defined by i) fever (temp \> 37.80 C), ii) leukocytosis (\>15,000 mm3) or increased immature neutrophils in blood (\>500 mm3), negative cultures and no other signs of infection.
Change in stool Bile Acids Composition pre and post FMT	8 Weeks
Changes in stool short chain free fatty acids pre and post FMT	8 weeks

Trial Locations

Locations (1)

University of Alberta Hospital; 🇨🇦 Edmonton, Alberta, Canada